CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

How Data Science is Revolutionizing Genomics

How Data Science is Revolutionizing...

Human-specific Proteins Uncovered by Exploring Genetic Uncharted Territory

Human-specific Proteins Uncovered by...

A Broader Perspective of Genomics

A Broader Perspective of Genomics

The Future Of Genomics In Theory-Focused Approaches

The Future Of Genomics In...

Role of Human Genomic Data in Future

Role of Human Genomic Data in Future

Essentiality of Single-cell Genomics Technology

Essentiality of Single-cell Genomics...

Tactics to Handle Genomic Data

Tactics to Handle Genomic Data

Benefits of Advanced Genomic Testing

Benefits of Advanced Genomic Testing

How Data Science is Revolutionizing Genomics

How Data Science is Revolutionizing...

Human-specific Proteins Uncovered by Exploring Genetic Uncharted Territory

Human-specific Proteins Uncovered by...

A Broader Perspective of Genomics

A Broader Perspective of Genomics

The Future Of Genomics In Theory-Focused Approaches

The Future Of Genomics In...

Role of Human Genomic Data in Future

Role of Human Genomic Data in Future

Essentiality of Single-cell Genomics Technology

Essentiality of Single-cell Genomics...

Tactics to Handle Genomic Data

Tactics to Handle Genomic Data

Benefits of Advanced Genomic Testing

Benefits of Advanced Genomic Testing

NeuBase Therapeutics Appoints New Chief Business and Strategy Officer

Life Sciences Review Life Sciences Review | Tuesday, August 24, 2021
Tweet

Dr. Motesharei has over 20 years of expertise in the biotechnology and pharmaceutical industries, including business development, alliance management, licensing and transactions, and strategy.


FREMONT, CA: NeuBase Therapeutics, a biotechnology company advancing the genetic revolution with a new class of precision genetic therapeutics, announced Kia Motesharei, Ph.D., as Chief Business and Strategy Officer, starting May 24, 2021. Dr. Motesharei has over 20 years of expertise in the biotechnology and pharmaceutical industries, including business development, alliance management, licensing and transactions, and strategy.


“Kia has successfully completed more than 100 deals, with particular expertise in scaling the output of platform biotechnology companies through partnerships to maximize shareholder value, with several drugs on market now as a direct result of his activities. Kia also has expertise in our programmatic areas including in neurology, oncology and rare diseases,” said Dietrich A. Stephan, Ph.D., Founder, CEO, and Chairman, NeuBase. “We are excited to welcome Kia to the NeuBase team, as we evaluate potential partnership opportunities and expand our therapeutic pipeline, leveraging the broad capabilities of our PATrOLTM platform for precision genetic medicines.”


Dr. Motesharei was most recently Senior Vice President, Business Development & Corporate Strategy at Akcea Therapeutics, a rare disease biopharmaceutical company in late-stage development and commercialization. He led and executed the regional partnership of Akcea’s marketed products Tegsedi and Waylivra with Sobi in Europe and the Middle East. Dr. Motesharei was previously the head of Global Licensing & Business Development, Neurology & Immunology (N&I) at EMD Serono, Merck KGaA’s biopharmaceutical division.


Check Out This: Business Management Review


“Genetic mutations are the fundamental drivers of all diseases, rare and common, so NeuBase’s ability to specifically modulate mutated DNA and RNA can unlock a whole new class of medicines for diseases that currently have few treatment options,” said Dr. Motesharei. “I look forward to utilizing partnership strategies to expand the breadth of what we have the potential to accomplish with this technology to benefit patients around the world.”


He was a key member of the N&I Franchise Leadership Team, which was in charge of executing the $1.8 billion franchise’s overall strategy, which included product and pipeline development, partnering, regulatory, commercial, and marketing choices. In addition, he oversaw the global licensing team, which was in charge of searching for, evaluating, and closing deals in the immunology, neurology, allergy, fertility, medical device, and global health businesses.


Dr. Motesharei was previously a member of Dyax Corporation’s management team and investor relations team, where he worked on developing and marketing innovative biotherapeutics to prevent hereditary angioedema. Additionally, he was in charge of business development, alliance management, and competitive intelligence for Dyax’s phage display platform and pipeline medicines such as Kalbitor and DX-2930 (now approved as Takhzyro), all of which contributed to Shire’s $6.5 billion acquisition. He formerly worked at Genfit Corporation, ActivX Biosciences, and Lion Bioscience, where he held several leadership positions.


He is now a member of the Ariana Pharma board of directors. Dr. Motesharei graduated from Colorado College with a B.A. in chemistry and a Ph.D. in organic chemistry from UCLA. At The Scripps Research Institute, he finished his postdoctoral training as an NIH fellow.


Weekly Brief

loading
Top 10 Genomics Solutions Companies in Europe/UK – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/neubase-therapeutics-appoints-new-chief-business-and-strategy-officer-nwid-389.html